Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y1FO
|
|||
| Former ID |
DIB008120
|
|||
| Drug Name |
Rubitecan
|
|||
| Synonyms |
9-Nitrocamptothecin; 91421-42-0; Orathecin; 9-nitro-20(S)-camptothecin; Camptogen; 9-NC; RFS 2000; RFS-2000; UNII-H19C446XXB; Nitrocamptothecin; H19C446XXB; CHEBI:90225; C20H15N3O6; (S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NCGC00167969-01; (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; 9NC; Q-100889; (4s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; Inhaled Orathecin; L9NC; Rubitecan (inhaled); Aerosolized liposomal 9 nitro-20 (S) camptothecin; Rubitecan (inhaled), SuperGen; 9-Nitro-20(S)-camptothecin; 9-Nitrocamptothecin (9-NC)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 3 | [1] | |
| Company |
SuperGen; Clayton Foundation For Research; MD Anderson Cancer Center
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H15N3O6
|
|||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O
|
|||
| InChI |
1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1
|
|||
| InChIKey |
VHXNKPBCCMUMSW-FQEVSTJZSA-N
|
|||
| CAS Number |
CAS 91421-42-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:90225
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2], [3] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00005869) Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9. | |||
| REF 3 | A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer. 2003 Jan 1;97(1):148-54. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.